Skip to main content

Table 1 Demographic and clinical characteristics: Chinese patients in the EINSTEIN DVT and EINSTEIN PE studies*

From: Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies

Characteristic

Rivaroxaban (n=220)

Standard therapy (n=219)

Mean age, years

58.6 ± 15.8

59.0 ± 15.0

Male sex, n (%)

127 (57.7)

112 (51.1)

Weight, n (%)

  

 ≤50 kg

11 (5.0)

15 (6.8)

 >50–80 kg

182 (82.7)

188 (85.8)

 >80 kg

25 (11.4)

16 (7.3)

 Missing data

2 (0.9)

0

Creatinine clearance, n (%)

 <30 mL/min

1 (0.5)

0

 30–<50 mL/min

19 (8.6)

28 (12.8)

 50–<80 mL/min

75 (34.1)

72 (32.9)

 ≥80 mL/min

117 (53.2)

116 (53.0)

 Missing data

8 (3.6)

3 (1.4)

Diagnostic method, PE cohort, n (%)

 Spiral computed tomography

99 (86.8)

102 (87.9)

 Ventilation–perfusion lung scanning

11 (9.6)

10 (8.8)

 Pulmonary angiography

3 (2.6)

1 (0.9)

 Not confirmed/not evaluable

1 (0.9)

3 (2.6)

Anatomical extent of PE, n (%)

 Limited: ≤25% of vasculature of a single lobe

13 (11.4)

10 (8.6)

 Intermediate

67 (58.8)

73 (62.9)

 Extensive: multiple lobes and >25% of entire pulmonary vasculature

30 (26.3)

29 (25.0)

 Not assessable

4 (3.5)

4 (3.4)

Diagnostic method, DVT cohort, n (%)

 Ultrasonography

130 (90.9)

120 (89.6)

 Venography

1 (0.7)

3 (2.2)

 Computed tomography scan

4 (2.8)

1 (0.7)

 Not confirmed/not evaluable

6 (4.2)

9 (6.7)

Anatomical extent of proximal DVT, n (%)

 Limited (popliteal vein or more distal)

25 (17.5)

17 (12.7)

 Intermediate (most proximal: superficial femoral vein)

25 (17.5)

27 (20.1)

 Extensive (most proximal: common femoral or iliac vein)

112 (78.3)

108 (80.6)

Time from onset of symptoms to randomization, days

 Median

9.0

9.0

 Interquartile range

4.0–19.0

4.0–20.0

Cause of DVT or PE, n (%)

 Unprovoked

164 (74.5)

162 (74.0)

 Secondary DVT or PE

56 (25.5)

57 (26.0)

 Recent surgery or trauma

34 (15.5)

39 (17.8)

 Immobilization

21 (9.5)

24 (11.0)

 Estrogen therapy

2 (0.9)

4 (1.8)

 Active cancer

6 (2.7)

7 (3.2)

 Puerperium

2 (0.9)

4 (1.8)

 Previous DVT or PE

27 (12.3)

36 (16.4)

  1. *Plus–minus values are means ± SD. There were no significant differences between the two study groups. Percentages may not total 100 because of rounding.
  2. Patients could have multiple causes of DVT or PE.
  3. DVT, deep-vein thrombosis; PE, pulmonary embolism; SD, standard deviation.